BillionToOne IPO Targets $265M ARR, Nears Profitability

Ticker: BLLN · Form: S-1/A · Filed: Oct 17, 2025 · CIK: 2070849

Sentiment: mixed

Topics: Precision Diagnostics, IPO, Biotechnology, Genetic Testing, Oncology, Prenatal Screening, Emerging Growth Company

TL;DR

**BLLN's IPO is a high-growth, high-risk bet on precision diagnostics, but the dual-class structure gives founders too much control for my taste.**

AI Summary

BillionToOne, Inc. (BLLN) is launching its initial public offering of 3,846,000 shares of Class A common stock, priced between $49.00 and $55.00 per share. The company reported an annualized revenue run-rate (ARR) of $265 million in Q2 2025, reflecting an 84% year-over-year growth. Its last twelve months (LTM) revenue as of June 30, 2025, was $209 million, demonstrating a 167% CAGR from 2021-2024. BillionToOne is nearing profitability, with a Q2 2025 EBITDA of $0.01 million and a net loss of ($0.2 million), significantly improving from a ($42 million) net loss in 2024. The company's gross profit margin reached 65% in H1 2025, a 14 percentage point increase year-over-year. Key risks include reliance on a dual-class stock structure, where Co-Founders Oguzhan Atay and David Tsao will control approximately 64.4% of voting power, and the competitive landscape in precision diagnostics. The strategic outlook focuses on expanding its diagnostic platform, which has already processed over 1 million tests since launch, into a $100 billion U.S. annual market opportunity, including future early detection products.

Why It Matters

BillionToOne's IPO introduces a high-growth precision diagnostics player to the public market, offering investors exposure to a company with an impressive 167% revenue CAGR (2021-2024) and emerging profitability. The dual-class stock structure, granting Co-Founders 64.4% voting power, means investors will have limited influence on corporate governance, a critical consideration. For patients and the broader healthcare market, BillionToOne's UNITY Fetal Risk Screen and Northstar Select tests represent advancements in early disease detection and personalized treatment, potentially disrupting traditional diagnostic methods and intensifying competition with established players in the diagnostics space.

Risk Assessment

Risk Level: high — The risk level is high due to the dual-class stock structure, where Co-Founders Oguzhan Atay and David Tsao will collectively own 100% of Class B common stock and approximately 64.4% of the total voting power post-IPO. This concentration of voting power means public shareholders will have limited influence on key corporate decisions. Additionally, the company is an 'emerging growth company,' which allows for reduced public company reporting requirements, potentially limiting transparency for investors.

Analyst Insight

Investors should carefully weigh BillionToOne's impressive 167% revenue CAGR and emerging profitability against the significant governance risks posed by the dual-class stock structure. Consider a smaller allocation if you believe in the long-term potential of their diagnostic technology, but be aware of the limited shareholder control.

Financial Highlights

debt To Equity
N/A
revenue
$209M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$0.2M
eps
N/A
gross Margin
65%
cash Position
N/A
revenue Growth
+167%

Revenue Breakdown

SegmentRevenueGrowth
Diagnostic Services$209M+167%
Q2 2025 ARR$265M+84%

Executive Compensation

NameTitleTotal Compensation
Oguzhan AtayCo-Founder, Chief Executive Officer and Chairman$340,000
David TsaoCo-Founder and Chief Scientific Officer$330,000

Key Numbers

Key Players & Entities

FAQ

What is BillionToOne's current revenue growth and profitability status?

BillionToOne reported an annualized revenue run-rate of $265 million in Q2 2025, representing an 84% year-over-year growth. The company is nearing profitability, with a Q2 2025 EBITDA of $0.01 million and a net loss of ($0.2 million), a significant improvement from a ($42 million) net loss in 2024.

What is the expected IPO price range for BillionToOne's Class A common stock?

The initial public offering price for BillionToOne's Class A common stock is expected to be between $49.00 and $55.00 per share, with 3,846,000 shares being offered.

How much voting power will BillionToOne's co-founders retain after the IPO?

Following the IPO, Co-Founders Oguzhan Atay and David Tsao will beneficially own 100% of the outstanding Class B common stock, resulting in approximately 64.4% of the total voting power of BillionToOne's outstanding capital stock.

What are the key products offered by BillionToOne?

BillionToOne offers diagnostic products such as the UNITY Fetal Risk™ Screen, which detects fetal risk for severe diseases from a maternal blood sample, and Northstar Select®, a blood test for oncology that identifies actionable cancer variants like EGFR mutation at 0.05% VAF.

What is BillionToOne's estimated total addressable market in the US?

BillionToOne estimates its US annual market opportunity to be $100 billion. Half of this addressable market includes early detection, an area where the company has not yet begun specific product development or commercial sales.

What is the significance of BillionToOne being an 'emerging growth company'?

As an 'emerging growth company' under U.S. federal securities laws, BillionToOne has elected to comply with certain reduced public company reporting requirements, which may impact the level of financial and operational disclosure available to investors.

How many tests has BillionToOne processed since its launch?

BillionToOne has processed over 1 million tests accessioned since its launch, with 508,000 LTM tests accessioned as of June 30, 2025, reflecting a 51% year-over-year growth in test volume.

What are the primary risks associated with investing in BillionToOne's Class A common stock?

Investing in BillionToOne's Class A common stock involves a high degree of risk, primarily due to the dual-class stock structure that grants Co-Founders Oguzhan Atay and David Tsao significant control (64.4% voting power), limiting public shareholder influence.

Who are the lead underwriters for BillionToOne's IPO?

The lead underwriters for BillionToOne's IPO include J.P. Morgan, Piper Sandler, Jefferies, William Blair, Stifel, Wells Fargo Securities, and BTIG.

What is BillionToOne's gross profit margin and how has it changed?

BillionToOne achieved a 65% gross profit margin in H1 2025, which represents a 14 percentage point year-over-year increase, indicating improved operational efficiency and cost management.

Risk Factors

Industry Context

BillionToOne operates in the rapidly evolving precision diagnostics market, a segment poised for significant growth driven by advancements in genetic sequencing and personalized medicine. The U.S. market opportunity is estimated at $100 billion annually, encompassing a wide range of diagnostic tests and future early detection solutions. The competitive landscape includes established diagnostic companies and innovative startups, all vying for market share through technological differentiation and strategic partnerships.

Regulatory Implications

As a diagnostics company, BillionToOne faces significant regulatory scrutiny, particularly from the FDA. Compliance with evolving regulations for diagnostic tests and medical devices is critical. Any missteps in regulatory adherence could lead to delays in product launches, market access restrictions, or costly remediation efforts, impacting the company's growth trajectory.

What Investors Should Do

  1. Evaluate the long-term impact of the dual-class stock structure on corporate governance and shareholder rights.
  2. Assess the company's ability to scale its diagnostic platform and operations to capture the $100 billion market opportunity.
  3. Analyze the competitive positioning and differentiation of BillionToOne's diagnostic platform against established and emerging players.
  4. Monitor the company's path to sustained profitability, given its near-breakeven EBITDA in Q2 2025.

Key Dates

Glossary

Annualized Revenue Run-Rate (ARR)
A projection of a company's total revenue over the next 12 months, based on its current revenue performance. (Indicates BillionToOne's strong current revenue trajectory, reaching $265 million in Q2 2025.)
Compound Annual Growth Rate (CAGR)
The mean annual growth rate of an investment over a specified period of time longer than one year. (Highlights BillionToOne's sustained high growth, with a 167% CAGR from 2021-2024.)
EBITDA
Earnings Before Interest, Taxes, Depreciation, and Amortization. A measure of a company's operating performance. (Shows BillionToOne is nearing profitability, with $0.01 million in Q2 2025.)
Dual-Class Stock Structure
A corporate structure where a company issues different classes of stock with different voting rights. (A key risk factor for BillionToOne, as it concentrates voting power with the co-founders (64.4%).)
Last Twelve Months (LTM)
A financial reporting period covering the most recent 12 months. (Used to report $209 million in revenue and 508,000 tests accessioned as of June 30, 2025.)
Gross Profit Margin
The percentage of revenue that exceeds the cost of goods sold. (Indicates improved efficiency for BillionToOne, reaching 65% in H1 2025.)

Year-Over-Year Comparison

The S-1/A filing shows a significant acceleration in BillionToOne's financial performance compared to previous periods. Revenue growth remains exceptionally strong, with an 84% year-over-year increase in Q2 2025 and a substantial 167% CAGR from 2021-2024, indicating robust market adoption. Gross profit margins have improved by 14 percentage points to 65% in H1 2025, demonstrating enhanced operational efficiency. The company is also nearing profitability, with Q2 2025 EBITDA at $0.01 million, a marked improvement from prior losses. New risks highlighted include the concentration of voting power due to the dual-class stock structure, which grants co-founders 64.4% control.

Filing Stats: 4,670 words · 19 min read · ~16 pages · Grade level 11.6 · Accepted 2025-10-17 17:13:50

Key Financial Figures

Filing Documents

Risk factors

Risk factors 22 Special note regarding forward-looking statements 80 Market, industry and other data 82

Use of proceeds

Use of proceeds 83 Dividend policy 84 Capitalization 85

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 91

Business

Business 129 Management 196

Executive compensation

Executive compensation 203 Certain relationships and related party transactions 214 Principal stockholders 219

Description of capital stock

Description of capital stock 222 Shares eligible for future sale 229 Material U.S. federal income tax consequences to non-U.S. holders of our Class A common stock 232

Underwriting

Underwriting 237 Legal matters 251 Experts 251 Where you can find additional information 251 Index to financial statements F-1 Through and including , 2025 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. Table of Contents For investors outside the United States: Neither we nor any of the underwriters have taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. Table of Contents Letter from Our Co-

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing